A retrospective nationwide analysis of evolocumab use in Sweden and its effect on low-density lipoprotein cholesterol levels
Upsala Journal of Medical Sciences · 2024
DOI: 10.48101/ujms.v129.9618 ↗Kurz gefasst
Fachartikel in der Zeitschrift Upsala Journal of Medical Sciences, 2024. Verfasst von Maria K Svensson und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Anticholesteremic Agents, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Treatment with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduces low-density lipoprotein cholesterol (LDL-C) levels and decreases the incidence of major ischaemic events in clinical trials. However, less is known about the efficacy of PCSK9 inhibition in clinical practice. This study aimed to describe the change in LDL-C levels over time and LDL-C goal achievement in patients with/without atherosclerotic cardiovascular disease (ASCVD), who were prescribed evolocumab in clinical practice, and to describe adherence to and persistence with treatment.
Methods
Patients in Sweden with at least one evolocumab prescription filled between July 2015 and May 2020 were included. Medical history and lipid-lowering therapy (LLT) were sourced from national registries. LDL-C levels before and after treatment initiation were assessed using medical records. Persistence with and adherence to evolocumab and oral LLT were assessed up to 12 months after treatment initiation using the refill-gap method and proportion of days covered, respectively.
Results
Of the 2,360 patients with at least one prescription for evolocumab, 2,341 were included; 1,858 had ASCVD. Persistence with (76%) and adherence to (86%) evolocumab were high throughout the 12 months following initiation. Mean LDL-C levels decreased by 53% (95% confidence interval [CI]: 51–55%) in patients adherent to evolocumab (n = 567) and 59% (95% CI: 55–63%) in patients adherent to evolocumab and oral LLT (n = 186). Similar reductions in LDL-C were observed in patients with/without ASCVD. Reduced LDL-C levels remained stable during follow-up. Amongst patients adherent to evolocumab and those adherent to evolocumab and oral LLT, 23 and 55% achieved the LDL-C goal of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
- Uppsala Clinical Research Centre, Uppsala, Sweden.
- Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
- Health Economics & Outcomes Research, Amgen (Europe) GmbH, Rotkreuz, Switzerland.
- Medical Affairs, Amgen AB, Stockholm, Sweden.
- Sence Research, Uppsala, Sweden.
Zitieren
APA
Svensson, M. K., James, S., Ravn-Fischer, A., Villa, G., Schalin, L., Cars, T., Gustafsson, S., & Hagström, E. (2024). A retrospective nationwide analysis of evolocumab use in Sweden and its effect on low-density lipoprotein cholesterol levels. Upsala Journal of Medical Sciences. https://doi.org/10.48101/ujms.v129.9618
Vancouver
Svensson MK, James S, Ravn-Fischer A, Villa G, Schalin L, Cars T, et al. A retrospective nationwide analysis of evolocumab use in Sweden and its effect on low-density lipoprotein cholesterol levels. Upsala Journal of Medical Sciences. 2024. doi:10.48101/ujms.v129.9618
BibTeX
@article{Svensson2024,
author = {Svensson, Maria K and James, Stefan and Ravn-Fischer, Annica and Villa, Guillermo and Schalin, Lovisa and Cars, Thomas and Gustafsson, Stefan and Hagström, Emil},
title = {A retrospective nationwide analysis of evolocumab use in Sweden and its effect on low-density lipoprotein cholesterol levels},
journal = {Upsala Journal of Medical Sciences},
year = {2024},
doi = {10.48101/ujms.v129.9618}
}
EUVIMED